SLC7A11 and cancer: We analyzed the CRISPR- and RNAi-based data in DEPMAP, and the results derived from 989 to 709 cell lines, respectively, showed SLC7A11 knockout or knockdown barely compromised the proliferation ability of all kinds of tumor cells (Figure 3A), which suggested SLC7A11 is associated with the worse prognosis of cancer patients through other mechanisms, tumor microenvironment, for example.